A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571Phase 3Active, not recruiting
- Lead sponsor
- Akero Therapeutics, Inc (Industry)
- Enrollment
- 700 (estimated)
- Start date
- 10 Nov 2023
- Primary completion
- 3 Mar 2026 (actual)
- Study completion
- 19 Jun 2026
- Last update posted
- 30 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- Efruxifermin Drug
- Placebo Drug
Conditions and primary outcome
- NASH/MASH
- NAFLD/MASLD
Primary outcome
Extent of exposure (52 Weeks); Number of participants with adverse events (52 Weeks); Number of participants with adverse events by severity (52 Weeks); Number of participants with clinically significant changes in clinical assessments (52 Weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06161571.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06161571 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.